摘要
去甲斑蝥素(norcantharidin,NCTD)是我国自行研制的一种抗癌药物,临床上具有广谱抗癌活性,并可升高外周血白细胞水平,常单独或与其他药物联合用于治疗肝癌、食道癌、胃癌、肺癌等。近年来为提高NCTD的抗肿瘤活性、减轻其可能的不良反应,以NCTD为前体的结构改造及与其他药物的联合使用等取得一定研究成果。本文通过对以NCTD为前体的新型抗癌化合物合成及筛选、NCTD联合其他药物抗癌的基础与临床研究最新进展进行综述,为基于NCTD的抗癌药物研发及临床应用提供参考。
Norcantharidin (NCTD) is an anticancer drug developed in China.It has broad-spectrum anticancer activity and can increase the level of peripheral blood leukocytes.It is often used alone or in combination with other drugs to treat liver cancer,esophageal cancer,stomach cancer,lung cancer,etc.To improve the antitumor activity and reduce its possible adverse reaction,the structure modification and drug combination of NCTD have made some progress in recent years.This paper tried to summarize the latest progress in structure modification and anticancer screening of NCTD,basic research and clinical studies of NCTD combined with other anticancer drugs,providing reference data for NCTD based new drug development and clinical application.
作者
李轶群
孙震晓
LI Yiqun;SUN Zhenxiao(School of Life Science,Beijing University of Chinese Medicine,Beijing 100102,China)
出处
《中国药物警戒》
2019年第3期179-184,共6页
Chinese Journal of Pharmacovigilance
基金
国家自然科学基金(81473418):肝细胞色素P450酶表达低下致何首乌特异质肝毒性机制研究
关键词
去甲斑蝥素
抗癌
结构改造
联合用药
不良反应
norcantharidin
anticancer
structure modification
drug combination
adverse reaction
